Head and Neck Cancer (Squamous Cell)

    Actionable Target Abnormality Prevalence Clinical Experience with Targeted Agent
    PD-1/PD-L1 N/A 90% (all HNSCC) Nivolumab (anti-PD-1 antibody) (FDA approved):
    • Phase 3: ORR 13.3% with nivolumab vs. 5.8% with investigator’s choice, mOS 7.5 mo with Nivo vs. 5.1 mo investigator’s choice (10)
    Pembrolizumab (anti-PD-1 antibody) (FDA approved):
    • Phase 1b: ORR 18% (11)
    Other topics in Targets by Organ Site